Empagliflozin for chronic heart failure and a reduced ejection fraction in patients with and without diabetes: primary results of the EMPEROR-Reduced trial

Thursday, 24 September 2020, 08:30 - 10:00, Klagenfurt Hall

Chair: M. Packer, US

J. Butler, US: Background and study design

M. Packer, US: Primary results

S.D. Anker, DE: Analysis of patients with and without diabetes

G. Filippatos, GR: Safety results

F. Zannad, FR: Meta-analysis of SGLT2 inhibitor heart failure trials

M. Packer, US: Concluding remarks and discussion of mechanism of effect

C.J. Bailey, UK: Commentary